Mirikizumab - Intravenous (IV)
27807
Phase 2 small_molecule active
Quick answer
Mirikizumab - Intravenous (IV) for Colitis, Ulcerative is a Phase 2 program (small_molecule) at Eli Lilly and Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly and Company
- Indication
- Colitis, Ulcerative
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active